Antipsychotic News and Research

RSS

Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.

Intentional substance exposures at school rise sharply among younger children

A new study found that rates of intentional substance exposures at school reported to U.S. poison centers increased substantially among elementary- and middle-school-aged children from 2000 through 2024, while high-school-aged adolescents continued to experience the highest rates of serious medical outcomes and hospital admissions.

28 Sep 2026

Add-on drug lumateperone boosts sexual function in patients with depression

Patients with major depressive disorder (MDD) and an inadequate response to standard antidepressants who received an add- on treatment with the drug lumateperone saw significantly improved sexual function, found a new study led by a University of Virginia School of Medicine researcher.

15 Sep 2026

LSD deconstruction reveals promising new drug candidates

University of California, Davis researchers have stripped down LSD to the base features responsible for its hallucinogenic and therapeutic effects.

7 Sep 2026

New brain atlas reveals insights into Huntington's, addiction, and other disorders

A region of the brain called the striatum is critical for many cognitive and motor functions, including decision-making, control of movement, habit formation, and processing of reward.

1 Sep 2026

Precision psychiatry aims to match schizophrenia patients with tailored medicines

Imagine watching a son or daughter begin college during a formative time in life, only to have schizophrenia suddenly alter their reality.

31 Aug 2026

Shifting expectations of unpredictability could help treat schizophrenia delusions

New research has found that improvements to the severity of delusions in patients with schizophrenia-spectrum disorder recovering from an acute psychotic episode were significantly associated with reductions in volatility priors—someone's expectations about the unpredictability of their environment.

18 Aug 2026

Single-dose psilocybin shows promise for treatment-resistant depression in NHS trial

A single 25-mg dose of psilocybin with psychological support was feasible to deliver within an NHS setting and produced large preliminary reductions in depressive symptoms among adults with treatment-resistant depression. The Phase 2 feasibility trial also found the treatment was generally well tolerated, although functional unblinding and expectancy effects mean larger, longer efficacy studies are needed.

10 Aug 2026

PET imaging reveals widespread brain receptor deficits in schizophrenia

A groundbreaking study using positron emission tomography (PET) imaging has found that patients with schizophrenia had significantly lower muscarinic acetylcholine M1 receptor availability (~13% to 19%) across multiple brain regions compared with healthy individuals.

16 Jul 2026

Semaglutide outperforms other GLP-1 drugs for weight loss in psychiatric populations

A network meta-analysis of nine randomized controlled trials found that once-weekly semaglutide showed the largest estimated weight-loss effect among GLP-1 receptor agonists tested in adults with mental illness and obesity or related metabolic risk. The authors cautioned that the findings remain preliminary because the evidence base was small, heterogeneous, and largely indirect.

9 Jul 2026

New sedative prescriptions increase fall risks for discharged older adults

Older adults discharged from hospital with a new prescription for a sedative, especially a benzodiazepine or antipsychotic, are at increased risk of falls and other negative consequences, according to new research published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.251965.

29 Jun 2026

Large study uncovers brain network differences in bipolar disorder

New research from the Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI) at the Keck School of Medicine of USC has discovered subtle but widespread differences in the brain's communication networks in people with bipolar disorder, offering new insight into how illness severity and treatment may relate to brain wiring.

9 Jun 2026

Most college students with psychosis lack recommended combination treatment

Although the majority of students sought and received therapy or counseling in the past 12 months, less than 40 percent received the recommended combination of therapy/counseling and antipsychotic medication, suggesting potential barriers to accessing this medication.

20 May 2026

Emergency settings more likely to initiate risky medications for seniors

Initial prescriptions for medications affecting cognition, such as antipsychotics, are disproportionately likelier to come from acute and post-acute settings such as emergency rooms, hospitals and skilled nursing facilities than they are from doctors' offices, new UCLA research suggests.

28 Apr 2026

CBD shows promise, but this review warns the hype is outpacing the science

A Neuropsychopharmacology Circumspectives article argues that cannabidiol has genuine therapeutic potential, especially in treatment-resistant pediatric epilepsy, but evidence for most other uses remains limited, heterogeneous, and not yet mature enough for broad clinical adoption. The authors also warn that poor retail product quality, inaccurate labeling, contaminants, hepatotoxicity risk, and drug interactions are major barriers to safe and effective real-world use.

20 Apr 2026